Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance

Journal of Experimental & Clinical Cancer Research

Jie Zhang²  Wei Li²  Zhenzhong Su²  Jinzhi Yin²  Minyu Xu²  Ping Li²  Qingshan Ma¹ 

[1] Department of Pediatrics, The First Affiliated Hospital of Jilin University, Changchun, China;Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, China

关键词: Cisplatin;    siRNA;    Chemotherapy;    Lung cancer;    Ku80;   

Others  :  825596
DOI  :  10.1186/1756-9966-31-99

 received in 2012-10-07, accepted in 2012-11-23,  发布年份 2012

【 摘 要 】

Background

Ku80 is crucially implicated in DNA repair, apoptosis, and chemoresistance. In this study, we aimed to assess the expression of Ku80 in clinical lung adenocarcinoma specimens, and investigate its role in the regulation of cisplatin sensitivity in cisplatin resistant human lung adenocarcinoma cells A549/DDP.

Methods

Tumor specimens and medical records of 106 patients with operable lung adenocarcinoma were obtained from 1998 to 2003. Ku80 mRNA and protein levels of the tumor samples, cultured human lung adenocarcinoma cells A549 cells and their cisplatin resistant variant A549/DDP cells were examined by reverse transcription PCR and western blot analysis. Ku80-specific siRNA or control scramble siRNA was transfected into A549/DDP cells, then cell sensitivity to cisplatin was examined by 3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide assay and apoptosis was assessed by flow cytometric analysis. In addition, the levels of cleaved caspase-3 and cleaved PARP in the treated cells were detected by western blot analysis.

Results

Total 83.3% (20/24) cisplatin-resistant tumors had high Ku80 expression, while 8.3% (4/48) cisplatin-sensitive tumors had high Ku80 expression (p < 0.01). Univariate analysis indicated that overall survival and progression-free survival were significantly better in lung adenocarcinoma patients with low vs. high Ku80 expression level (p < 0.01). Ku80 mRNA and protein expression levels were significantly increased in A549/DDP cells compared to parental A549 cells. siRNA mediated knockdown of Ku80 resensitized A549/DDP cells to cisplatin-induced apoptosis.

Conclusions

Ku80 expression level could predict the outcome and the sensitivity to cisplatin-based chemotherapy in patients with lung adenocarcima. Ku80-siRNA could be utilized as a therapeutic strategy to resensitize nonresponders to cisplatin.

【 授权许可】

   
2012 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Fan Z, Schraeder R: The changing pathology of lung cancer. Surg Oncol Clin N Am 2011, 20:637-653.
• [3]Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al.: American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV Non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
• [4]Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
• [5]Suzuki K, Kodama S, Watanabe M: Role of Ku80-dependent end-joining in delayed genomic instability in mammalian cells surviving ionizing radiation. Mutat Res 2010, 683:29-34.
• [6]Postow L, Ghenoiu C, Woo EM, Krutchinsky AN, Chait BT, Funabiki H: Ku80 removal from DNA through double strand break-induced ubiquitylation. J Cell Biol 2008, 182:467-479.
• [7]Wang HC, Liu CS, Chiu CF, Chiang SY, Wang CH, Wang RF, Lin CC, Tsai RY, Bau DT: Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res 2009, 29:5251-5254.
• [8]Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J: Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008, 112:2756-2764.
• [9]Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM: Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene 2001, 20:739-747.
• [10]Ye J, Ren ZY, Gu Q, Wang LM, Wang JL: Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice. DNA Cell Biol 2011, 30:987-994.
• [11]Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J, Salles B: Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 1999, 56:141-146.
• [12]Marme F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, et al.: Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer J int cancer 2012, 131:E586-591.
• [13]Muller C, Calsou P, Frit P, Cayrol C, Carter T, Salles B: UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells. Nucleic Acids Res 1998, 26:1382-1389.
• [14]Teng XD: World Health Organization classification of tumours, pathology and genetics of tumours of the lung. Zhonghua bing li xue za zhi Chinese journal of pathology 2005, 34:544-546.
• [15]Wrona A, Jassem J: The new TNM classification in lung cancer. Pneumonol Alergol Pol 2010, 78:407-417.
• [16]Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS: APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
• [17]Li P, Wang K, Zhang J, Zhao L, Liang H, Shao C, Sutherland LC: The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin. Cancer Epidemiol 2012, 36:481-489.
• [18]Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T: Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005, 106:3449-3456.
• [19]Chang IY, Youn CK, Kim HB, Kim MH, Cho HJ, Yoon Y, Lee YS, Chung MH, You HJ: Oncogenic H-Ras up-regulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 2005, 65:6811-6819.
• [20]Liang H, Zhang J, Shao C, Zhao L, Xu W, Sutherland LC, Wang K: Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res 2012, 31:36. BioMed Central Full Text
• [21]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
• [22]Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
• [23]Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31.
• [24]Wynne P, Newton C, Ledermann J, Olaitan A, Mould TA, Hartley JA: Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007, 97:927-933.
• [25]Gullo C, Au M, Feng G, Teoh G: The biology of Ku and its potential oncogenic role in cancer. Bba-Rev Cancer 2006, 1765:223-234.
• [26]Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
• [27]Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
• [28]Soldani C, Scovassi AI: Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
• [29]Li G, Nelsen C, Hendrickson EA: Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA 2002, 99:832-837.